Diabetes: GLP-1 Analogues, DPP-IV Inhibitors & Insulins Trends in Use

August 2007

Deliverable: Executive Summary and Quantitative Research Findings in PowerPoint Slides

Objective: To provide an overview of current type II diabetes mellitus (T2DM) treatment practices and the near-term market outlook for a set of companies and key therapeutic products in development.  Additionally:

§     Focus on experience with and outlook for three key drugs and classes: Byetta® (exenatide) and GLP-1 analogues, Januvia™ (sitagliptin) and DPP-IV inhibitors, and Exubera® (inhaled insulin) and insulins with novel delivery methods

§     Gauge awareness and excitement for pipeline agents in these classes, specifically the long acting GLP-1 analogues exenatide LAR and liraglutide and a set of novel insulins in development by MannKind Corporation, Nektar Therapeutics, Alkermes, and others

§     Clarify reasons for limited use of Exubera® and lack of excitement regarding inhaled insulins

§     Understand impact, if any, of Januvia™ availability on the acceptance and usage of Byetta®

§     Determine impact, if any, of recent news coverage and FDA review of Avandia® and its potential CV risks on physician prescribing practices

Products Highlighted:

§     Byetta® (exenatide), Amylin/Eli Lilly (LLY)

§     Exubera® (insulin human [rDNA origin] inhalation powder), Pfizer (PFE)

§     Januvia™ (sitagliptin), Merck (MRK)

§     Other companies: MannKind Corporation (MNKD), Nektar Therapeutics (NKTR), Alkermes (ALKS)

Topics:

§     Section 1: Focus on Byetta® and GLP-1 Analogues

§     Section 2: Focus on Januvia™ and DPP-IV Inhibitors

§     Section 3: Inhaled Insulin

§     Section 4: Recent Events and Outlook

Screening Criteria:

§     154 US-based endocrinologists and primary care physicians

§     Board-certified or board eligible

§     2 to 30 years of experience post-training

§     Minimum of 75% professional time spent in clinical practice

§     Minimum of 80 T2DM prescriptions per month

Reports become free one year after the publication date.